Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT: SC-CAR.GPC3xIL15.21 T cells for Pediatric Solid Tumors
NCT07148050Phase 1Recruiting
- Sponsor
- Seattle Children's
- Start
- Dec 2025
- Primary completion
- Apr 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SC-CAR.GPC3xIL15.21 in solid tumor, sponsored by Seattle Children's. Primary endpoints: Number of successfully manufactured SC-CAR.GPC3xIL15.21 T cell products at 28 days and Adverse Events at 28 days. Started Dec 2025; status: recruiting.
02
Drugs
SC-CAR.GPC3xIL15.21
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07148050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07148050.